BPR0C305, an orally active microtubule-disrupting anticancer agent.

abstract：:Long noncoding RNA (lncRNA) KTN1 antisense RNA 1 (KTN1-AS1) is a novel promoter in the progression of some cancers. However, the knowledge of its role in lung adenocarcinoma is still limited. The current study aimed to examine the biological functions of KTN1-AS1 and its coexpressed protein in lung adenocarcinoma. The...

journal_title：Anti-cancer drugs

authors： Li YY,Li W,Chang GZ,Li YM

更新日期：2021-01-22 00:00:00

abstract：:1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

journal_title：Anti-cancer drugs

authors： Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

更新日期：2000-06-01 00:00:00

abstract：:The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer. Secondary objectives included evaluation of the safety and efficacy of the regimen. Patients (n=19) with ...

journal_title：Anti-cancer drugs

authors： Schmid P,Krocker J,Schulz CO,Michniewicz K,Dieing A,Eggemann H,Heilmann V,Blohmer JU,Sezer O,Elling D,Possinger K

更新日期：2005-01-01 00:00:00

abstract：:The cytotoxic activity of bendamustine hydrochloride was evaluated against human ovarian and breast carcinoma cell lines including cell lines resistant to cisplatin and doxorubicin in vitro. The relative degree of resistance to bendamustine hydrochloride was lower in all cell lines compared with cyclophosphamide, melp...

journal_title：Anti-cancer drugs

authors： Strumberg D,Harstrick A,Doll K,Hoffmann B,Seeber S

更新日期：1996-06-01 00:00:00

abstract：:A functionalized poly(amidoamine) (PAMAM) nanocarrier was designed and prepared to deliver anticancer drugs. The nanocarrier is a copolymer with a core-shell structure with 3.0 G PAMAM as the core and sequentially conjugated poly(2-(N,N-diethylamino)ethyl methacrylate) (pDEA) and methoxy-poly(ethylene glycol) 2000 (mP...

journal_title：Anti-cancer drugs

authors： Du L,Jin Y,Yang J,Wang S,Wang X

更新日期：2013-02-01 00:00:00

abstract：:Anti-tubulin couplets have activity in hormone-resistant prostate cancer. This study was designed to define the dose-limiting toxicity (DLT) and recommended phase II dose (RPTD) of the unique triplet combination of paclitaxel, estramustine phosphate (EMP) and vinorelbine (Pacl-E-Vin). Patients with advanced malignanci...

journal_title：Anti-cancer drugs

authors： Sewak S,Chachoua A,Hamilton A,Taneja S,Lee J,Utate M,Sorich J,Muggia FM

更新日期：2003-01-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) remains incurable for most patients, and proteasome inhibitors like bortezomib induce responses in a minority of patients with relapsed disease. Fenretinide is a retinoid that has shown preclinical activity in B-cell lymphomas. We hypothesized that these agents could yield augmented antitumo...

journal_title：Anti-cancer drugs

authors： Cowan AJ,Frayo SL,Press OW,Palanca-Wessels MC,Pagel JM,Green DJ,Gopal AK

更新日期：2015-10-01 00:00:00

abstract：:The goal of our study was to determine whether an apoptosis assay used after short-term drug exposure could predict selective toxicity to cancer cells. To this end we compared the effect of eight anticancer drugs and 10 toxic compounds without known antitumor activity in cultures of human breast cancer cells and norma...

journal_title：Anti-cancer drugs

authors： Frankfurt OS,Krishan A

更新日期：2003-08-01 00:00:00

abstract：:Epidemiological and clinical studies suggesting a significant inverse relationship between intake of dietary selenium and overall cancer risk have led to initiation of a randomized, placebo-controlled, phase III clinical trial testing the safety and efficacy of selenized yeast as a chemopreventive agent for prostate c...

journal_title：Anti-cancer drugs

authors： Stratton MS,Reid ME,Schwartzberg G,Minter FE,Monroe BK,Alberts DS,Marshall JR,Ahmann FR

更新日期：2003-09-01 00:00:00

abstract：:A cost-utility analysis has been performed comparing taxanes, vinorelbine and standard therapy for metastatic breast cancer considering clinical efficacy, quality-adjusted-life-years (QALYs) and costs. A decision model has been built. Clinical efficacy data were collected by literature review. Utility data and cost da...

journal_title：Anti-cancer drugs

authors： Li N,van Agthoven M,Willemse P,Uyl-de Groot C

更新日期：2001-07-01 00:00:00

abstract：:The effect of association of hyperthermia with the anti-inflammatory drug rhein (RH), 4,5-dihydroxyanthraquinone-2-carboxylic acid, on the clonogenic activity of human glioma cells has been examined. RH inhibits neoplastic growth mainly through an ATP depletion, but thermal cell killing is not mediated by the drug-ind...

journal_title：Anti-cancer drugs

authors： Floridi A,Gentile PF,Bruno T,Delpino A,Iacobini C,Benassi M

更新日期：1992-08-01 00:00:00

abstract：:Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid...

journal_title：Anti-cancer drugs

authors： Pouessel D,Culine S

更新日期：2012-01-01 00:00:00

abstract：:beta-Lapachone is a naturally occurring quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae) with cancer chemopreventive properties. The objective of the present study was to investigate the effect of beta-lapachone on the cell growth and apoptosis in human colon carcinoma tumor cell line HCT-116....

journal_title：Anti-cancer drugs

authors： Choi BT,Cheong J,Choi YH

更新日期：2003-11-01 00:00:00

abstract：:This review focuses on the recent advances in chemotherapy of malignant gliomas, with special emphasis on the most common primary brain tumor in adults, glioblastoma. The demonstration of the superiority of concomitant and adjuvant temozolomide with standard radiotherapy over radiotherapy alone in patients with newly ...

journal_title：Anti-cancer drugs

authors： Soffietti R,Rudà R,Trevisan E

更新日期：2007-07-01 00:00:00

abstract：:Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clinical trials. The aims of this single-center, open label, phase I clinical trial were to investigate the safety and tolerability of CA4P admin...

journal_title：Anti-cancer drugs

authors： Liu P,Qin Y,Wu L,Yang S,Li N,Wang H,Xu H,Sun K,Zhang S,Han X,Sun Y,Shi Y

更新日期：2014-04-01 00:00:00

abstract：:The in vitro antitumor activity of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, was compared with that of adriamycin (ADM) against human breast carcinomas inoculated into nude mice at the maximum tolerated dose (MTD) and clinically equivalent dose (CED). The plasma levels of NVB after intravenous inje...

journal_title：Anti-cancer drugs

authors： Tsuruo T,Inaba M,Tashiro T,Yamori T,Ohnishi Y,Ashizawa T,Sakai T,Kobayashi S,Gomi K

更新日期：1994-12-01 00:00:00

abstract：:13,14-Dihydro-15-deoxy-Delta7-prostaglandin A1 methyl ester (TEI-9826), an antitumor prostaglandin analog, is a candidate for clinical trial. In the present study, we examined its biological stability in vitro, antitumor activity in vitro and in vivo, and pharmacokinetics. Although TEI-9826 was rapidly hydrolyzed to t...

journal_title：Anti-cancer drugs

authors： Fukushima S,Takeuchi Y,Kishimoto S,Yamashita S,Uetsuki K,Shirakawa S,Suzuki M,Furuta K,Noyori R,Sasaki H,Kikuchi Y,Kita T,Yamori T,Sawada J,Kojima M,Hazato A,Kurozumi S,Fukushima M

更新日期：2001-03-01 00:00:00

abstract：:The current reference treatment of hormone-refractory prostate cancer consists mainly of chemotherapy with docetaxel. To improve the management of advanced prostate cancer, one should examine the benefits of adding other agents to docetaxel. We examined the growth inhibitory effects of a triple combination, including ...

journal_title：Anti-cancer drugs

authors： Fischel JL,Ciccolini J,Formento P,Ferrero JM,Milano G

更新日期：2006-08-01 00:00:00

abstract：:Weekly and triweekly cisplatin-alone concomitant chemoradiotherapy regimens after radical surgery were compared in stages IB-IIA cervical cancer with intermediate- or high-risk factors to identify the better therapeutic regimen. We retrospectively analyzed patients with stages IB-IIA cervical cancer who received radic...

journal_title：Anti-cancer drugs

authors： Zhu J,Lou R,Ji S,Wu G,Chen Q,Hu Q,Zhao Y,Cai D,Gu K

更新日期：2021-02-01 00:00:00

abstract：:The antitumor effects of a polyamine biosynthetic pathway inhibitor methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on the human hepatocellular carcinoma SK-HEP-1 cell line have been investigated. The growth of these cultured hepatocellular carcinoma cells was inhibited by MGBCP in a dose-dependent manner. Sper...

journal_title：Anti-cancer drugs

authors： Hashimoto Y,Hibasami H,Tamaki S,Kamei A,Ikoma J,Kaito M,Imoto I,Watanabe S,Nakashima K,Adachi Y

更新日期：1999-03-01 00:00:00

abstract：:Trichostatin A and helixor A increased thrombospondin-1 expression by ECV304 cells at both mRNA and protein levels by transcriptional activation through the enhancement of tsp-1 promoter activity. The induction of thrombospondin-1 by these agents potently reduced ECV 304 cell migration and capillary-like tube formatio...

journal_title：Anti-cancer drugs

authors： Hong S,Chang SY,Yeom DH,Kang JH,Hong KJ

更新日期：2007-10-01 00:00:00

abstract：:Concurrent and pre-exposure of A431 human epidermoid cancer cells to UCN-01, an investigational anticancer drug, with 5-fluoro--2'-deoxyuridine (FdUrd), which targets thymidylate synthase, produced more than additive cytotoxicty. A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thym...

journal_title：Anti-cancer drugs

authors： Grem JL,Danenberg KD,Kao V,Danenberg PV,Nguyen D

更新日期：2002-03-01 00:00:00

abstract：:Twelve patients received intrapleural instilments of the cytostatic agent mitoxantrone in a total dosage of 30 mg for locoregional palliative therapy of malignant pleural effusion. Effusion could be stopped for a mean period of 3.2 months in 11 patients. ...

journal_title：Anti-cancer drugs

authors： Torsten U,Opri F,Weitzel H

更新日期：1992-02-01 00:00:00

abstract：:Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion. Thirty-six patients entered the study, and all of them were evaluable for response and toxi...

journal_title：Anti-cancer drugs

authors： Cascinu S,Graziano F,Cardarelli N,Marcellini M,Giordani P,Menichetti ET,Catalano G

更新日期：1998-04-01 00:00:00

abstract：:OncoGel is a novel depot formulation of paclitaxel designed for intralesional injection with a sustained paclitaxel delivery over approximately 6 weeks from a single administration. This phase 1 study was designed to characterize the toxicity, pharmacokinetics and preliminary antitumor activity associated with OncoGel...

journal_title：Anti-cancer drugs

authors： Vukelja SJ,Anthony SP,Arseneau JC,Berman BS,Cunningham CC,Nemunaitis JJ,Samlowski WE,Fowers KD

更新日期：2007-03-01 00:00:00

abstract：:Gossypol [(2,2'-binaphthalene)-8,8'-dicarboxaldehyde-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl] 1a is a naturally occurring compound extracted from the cotton plant and has been extensively studied as an oral male contraceptive. Its favorable toxicity profile, and the more recent demonstration of anti-...

journal_title：Anti-cancer drugs

authors： Shelley MD,Hartley L,Groundwater PW,Fish RG

更新日期：2000-03-01 00:00:00

abstract：:A lack of cross-resistance between the aromatase inhibitors (AIs) provides evidence to suggest that there are clinical differences between these agents. Available data from clinical trials indicate that patients exposed to nonsteroidal AIs may benefit from a steroidal compound of similar biochemical potency, and durab...

journal_title：Anti-cancer drugs

authors： Lønning PE

更新日期：2008-03-01 00:00:00

abstract：:Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

更新日期：2018-04-01 00:00:00

abstract：:Fibroblast growth factor-inducible 14 (Fn14) has been reported to play an oncogene role in many types of cancer. However, its biological functions in small-cell lung cancer (SCLC) remain unknown. The aim of this study is to investigate the roles of Fn14 in the cell growth and chemoresistance of SCLC and its possible m...

journal_title：Anti-cancer drugs

authors： Li X,Zhu W,Chen Z,Luo L,Huang J,Zhang F,Li M,Guo Y,Guo L

更新日期：2014-11-01 00:00:00

abstract：:The aim of this study was to establish xenograft models of tumor in mice bladder and evaluate the antitumor efficacy of ampelopsin sodium (Amp-Na). A total of 2×10 human bladder carcinoma EJ cells and murine sarcoma 180 cells were instilled into the bladder of BALB/c nu/nu mice and Swiss mice after preconditioning to ...

journal_title：Anti-cancer drugs

authors： Zhang B,Dong S,Cen X,Wang X,Liu X,Zhang H,Zhao X,Wu Y

更新日期：2012-07-01 00:00:00